MARKET

RUBY

RUBY

Rubius Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.80
+0.08
+0.35%
After Hours: 22.80 0 0.00% 16:00 07/29 EDT
OPEN
22.87
PREV CLOSE
22.72
HIGH
24.19
LOW
22.51
VOLUME
350.72K
TURNOVER
--
52 WEEK HIGH
38.71
52 WEEK LOW
4.200
MARKET CAP
2.04B
P/E (TTM)
-11.4515
1D
5D
1M
3M
1Y
5Y
BRIEF-Rubius Therapeutics Appoints Dannielle Appelhans As Chief Operating Officer
reuters.com · 17h ago
Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
marketwatch.com · 18h ago
Rubius Therapeutics appoints new operations chief
Rubius Therapeutics (NASDAQ:RUBY) appoints Dannielle Appelhans as COO, effective August 9, 2021. She will oversee corporate strategy and technical operations. Most recently, Ms. Appelhans served as senior vice president of technical operations and chief
Seekingalpha · 19h ago
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 ...
Insider Monkey · 1d ago
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM) for the treatment of cancer and auto...
GlobeNewswire · 07/22 12:30
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), today announced the publication of p...
GlobeNewswire · 07/15 12:00
Sector Update: Health Care Stocks Higher Late in Thursday Afternoon Session
MT Newswires · 06/24 16:06
Sector Update: Health Care Stocks Slip From Highs as Less Defensive Sectors Gain Favor
MT Newswires · 06/24 13:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RUBY. Analyze the recent business situations of Rubius Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RUBY stock price target is 30.40 with a high estimate of 40.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 87.25M
% Owned: 97.68%
Shares Outstanding: 89.32M
TypeInstitutionsShares
Increased
28
6.88M
New
32
3.38M
Decreased
33
1.26M
Sold Out
13
314.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Director
David Epstein
President/Chief Executive Officer/Director
Pablo Cagnoni
Chief Financial Officer
Jose Carmona
Chief Scientific Officer
Laurence Turka
Other
Christina Coughlin
Secretary
Maiken Keson-Brookes
Independent Director
Noubar Afeyan
Independent Director
Francis Cuss
Independent Director
Natalie Holles
Independent Director
Anne Prener
Independent Director
Michael Rosenblatt
Independent Director
Catherine Sohn
Independent Director
Jonathan Symonds
No Data
About RUBY
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Webull offers kinds of Rubius Therapeutics Inc stock information, including NASDAQ:RUBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RUBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RUBY stock methods without spending real money on the virtual paper trading platform.